

Myocardial Ischemia and Postoperative Monitoring

John E. Ellis, M.D.

Philadelphia, Pennsylvania

Myocardial Ischemia and Postoperative Monitoring

Introduction

Morbidity and mortality remain associated with coronary artery disease (CAD) in surgical patients, though likely less than in the past. Perioperative myocardial infarction (PMI) may be lethal or compromise a patient's functional status after surgery, and result in additional costs. Less-invasive surgery may lessen these risks. Attempts to improve perioperative outcome of patients at risk for having CAD have focused on 3 approaches: (i) preoperative identification of high-risk patients who might benefit from myocardial revascularization, (ii) improved detection of perioperative myocardial ischemia to allow for prompt therapeutic intervention, and (iii) the prophylactic use of anesthetic and antiischemic techniques to decrease the prevalence and severity of postoperative myocardial ischemia. Many of studies referenced have been undertaken in vascular surgery patients.

Myocardial Ischemia Vs. Myocardial Infarction:

Myocardial ischemia is the surrogate that is more often addressed in the research reviewed in this lecture. To demonstrate reductions in the rate of infarction (typically reported at ~ 5% in vascular surgical series) with a therapy requires thousands of patients and millions of dollars to show statistical differences. We now have multi-center trials in the anesthesia literature, the use of meta-analysis to combine the results of trials by different investigators of similar interventions, and the analysis of large databases and registries to evaluate therapies. Some of these suggest that examining only surrogate markers may be misleading.

Predictors And Prognosis:

Demographic predictors (prior probability). Risk factors may include known CAD, congestive heart failure, peripheral vascular disease, advanced age, severely limited exercise tolerance, chronic renal insufficiency, uncontrolled hypertension and left ventricular hypertrophy, impaired glucose tolerance and/or diabetes, and the use of digoxin. Evidence of decompensated heart disease, such as arrhythmias or CHF, appears particularly associated with adverse outcomes. Multifactorial indices, such as the RCRI, have been proposed to risk-stratify patients. Lee et al determined preoperative predictors of adverse cardiac events after noncardiac surgery in a large cohort; these predictors include previous MI, CHF, cerebrovascular disease, major surgery, and diabetes treated with insulin. Resting echocardiographic indicators (systolic dysfunction) may also have additive predictive value (above and beyond clinical risk factors) for predicting perioperative myocardial infarction in high-risk patients. The most recent AHA/ACC guidelines have deemphasized the role of preoperative stress testing, after the CARP study showed no benefit to preop stress testing and coronary revascularization before vascular surgery.

Dynamic postoperative predictors. Factors that may increase the likelihood of postoperative myocardial ischemia that we can control include tachycardia, anemia, hypothermia, shivering, hypoxemia, endotracheal suctioning, and less-than-optimal analgesia. For patients undergoing noncardiac surgery, perioperative MI may be associated with higher postoperative heart rates and higher pain thresholds, but not necessarily angina (most are silent). Other factors, such as postoperative hypercoagulability, and REM sleep rebound are more speculative culprits.

Prognosis. Postoperative myocardial ischemia confers increased risk to surgical patients. The longer the ischemic episode(s) and the greater the ST segment change, the worse the prognosis. Modern preop preparation, surgery, and anesthesia may be associated with less myocardial ischemia than in the past. We believe that patients with documented severe postoperative myocardial ischemia or troponin release should be referred to a cardiologist, since they are at high risk for adverse long-term cardiac outcomes. PMI is still associated with significant in-hospital mortality (in proportion to troponin elevation), and is a marker for poor prognosis after discharge in those who survive.

Detection of Myocardial Ischemia and Infarction:

Patients undergoing vascular surgery are most likely to manifest myocardial ischemia in the immediate

postoperative period, usually on the day of surgery or the next. The "silent" nature of postoperative ischemia suggests that frequent ECG monitoring may be useful. Unfortunately, approximately 1/4 of vascular surgery patients will have baseline ECG abnormalities (LBBB, paced rhythm, digoxin effect, LVH with strain) that preclude the detection of myocardial ischemia. Other techniques of ischemia detection, such as the presence of v-waves in the PCWP tracing or decrements in regional wall motion detected with TEE, are less useful after surgery because they are discontinuous, expensive, and relatively invasive. Troponin levels appear more specific in detecting perioperative myocardial infarction than CK-MB isoenzymes; troponin elevations are associated with lower survival after vascular surgery. Routine troponin surveillance appears to be cost effective after traditional AAA surgery.

Proposed Mechanisms Of Postoperative Myocardial Ischemia:

Stable ischemic syndromes presumably occur with increased oxygen demand on the myocardium in a setting of fixed coronary plaques. Unstable syndromes are thought to be the result of plaque rupture with local thrombus and vasoreactivity that produce intermittent critical decreases in coronary oxygen supply. Patients with elevated coronary calcium on CT scan have greater rates of perioperative MI after vascular surgery. Endothelial function is impaired in CAD, hypertension, hypercholesterolemia, diabetes, and tobacco abuse, resulting in exaggerated vasoconstriction. Poor endothelial function is also associated with poor outcome after vascular surgery. Treatment to "heal" the endothelium (often with statin drugs) improves perioperative outcome, though effective therapy may have to begin weeks before surgery. Also, in patients with left ventricular hypertrophy (LVH), diminished coronary vasodilator reserve results in poor subendocardial perfusion. Early postoperative ischemia is usually associated with ST segment depression rather than ST elevation. ST segment depression usually precedes postoperative cardiac complications. Most perioperative MIs are of the non-Q wave variety.

The postoperative period is characterized by adrenergic stress, which can induce myocardial ischemia in patients with CAD; cause coronary vasoconstriction, and facilitate platelet aggregation. Tachycardia limits diastolic time and coronary perfusion, and it can paradoxically reduce coronary artery diameter. Hypertension and tachycardia in the PACU have been shown in a large study to be associated with increased mortality and unplanned ICU admission (although association does not necessarily mean causation.)

Surgery can induce a hypercoagulable response due to increased platelet number and function, diminished fibrinolysis, decreases in protein C and antithrombin III, and increases in procoagulants (including fibrinogen, factor VIII coagulant, and von Willebrand factor). These postoperative changes may contribute to an increased likelihood of coronary thrombosis in the postoperative period, but their relative importance in predicting postoperative coronary events remains speculative. TEG may identify high-risk patients.

Cardiologists and internists are increasingly undertaking aggressive long-term pharmacologic risk reduction in patients with CAD. These strategies include cholesterol reduction with statins (which stabilize coronary plaques and reduce inflammation), antihypertensive therapy with ACE inhibitors and/or ARBs, and "tighter" glucose control in diabetics. These patients may be more prone to perioperative hypotension, bradycardia, and hypoglycemia.

Prophylaxis And Treatment Of Postoperative Myocardial Ischemia:

Beta Blockers. Beta adrenergic blocking drugs, through their ability to suppress perioperative tachycardia, appear most efficacious in preventing perioperative myocardial ischemia. They are well tolerated by most surgical patients and may reduce long-term cardiac events. Beta adrenergic blocking drugs have been approved for treatment of hypertension, supraventricular tachycardias, ventricular arrhythmias, angina, and myocardial infarction. They are a cornerstone of chronic post-MI therapy, as they reduce subsequent reinfarction. Antihypertensive effects of beta blockers are useful during adrenergic activation during events such as endotracheal intubation, extubation, ECT, and sternotomy. They also blunt tachycardia at these times, and this is likely the predominant mechanism of their antiischemic effects. Several trials which document the ability of beta blockers to improve perioperative cardiac outcomes have been published, though several very recent trials have questioned this conclusion. Recent work suggests that beta blockade is most efficacious in patients with many clinical risk factors and/or positive stress tests. The outcome benefit from perioperative blockade may persist for up to two years after vascular surgery in high-risk patients. Beta1 selective drugs are less likely to cause bronchospasm, even in patients with reactive airway disease. Still, asthma and COPD are relatively contraindications to beta blockade. There is a very small subset of patients with severe coronary artery disease (floridly positive stress tests in multi-vessel distributions) who appear not to benefit from beta blockade; such patients may be considered candidates for myocardial revascularization. Recent trials (MAVS, DIPOM) have questioned the perioperative protective effects of beta blockade. A recent (n=430 very high risk patients) Dutch RCT (DECREASES-V) suggests that HR control to 60 bpm with titrated beta blockade is better than stress testing +/- coronary revascularization. The larger POISE trial (n= 8351), however, suggests that

while fixed-dosed beta blockade with metoprolol lowers rates of myocardial infarction and atrial fibrillation, these improvements come at the cost of increased stroke and death. POISE used a fixed, maximal dose of metoprolol; some have suggested that better outcomes would have followed had the drug been titrated to hemodynamics. The POISE trial may result in the scaling-back of CQI and P4P initiatives aimed at increasing the use of periop beta blockade.

Other anti-anginal drugs appear less promising. Two studies, one in noncardiac surgery, and one in fast-track CABG surgery, have found that prophylactic intravenous nitroglycerin failed to reduce the prevalence of perioperative myocardial ischemia or infarction. This may have been due to compensatory increases in heart rate. The short-acting calcium antagonist nifedipine may increase mortality after acute MI and should probably not be used as a first line drug for acute control of hypertension in patients with CAD.

Epidural Analgesia. Epidural anesthetics reduce cardiac preload and afterload, postoperative adrenergic and coagulation responses, and produce coronary vasodilatation (thoracic epidurals only). These effects suggest that they may reduce perioperative myocardial ischemia. However, evidence of benefits in cardiac outcome has been limited in individual trials. Concerns about respiratory depression, neuroaxis hematomas, and the expense of surveillance have limited the use of peridural narcotics in greater numbers of patients. Epidural anesthesia may improve other organ system outcomes, but its ability to reduce myocardial infarction remains speculative. Providing aggressive postoperative analgesia may be labor-intensive, and the cost-effectiveness remains unclear at this time. Two recent meta-analyses suggest that regional anesthesia may indeed be associated with a one-third reduction in perioperative myocardial infarction, especially if spinals or thoracic epidurals are used.

Volatile Anesthetics. Volatile anesthetics reduce myocardial infarct size. The preconditioning effects of volatile anesthetics suggest that they should be incorporated into general anesthetic techniques for patients with known or suspected coronary artery disease.

Non-steroidal anti-inflammatory drugs (NSAIDs) might be particularly useful in surgical patients with coronary artery disease due to their analgesic and antiplatelet effects. Ketorolac may reduce the stress response to surgery without increasing bleeding times or producing renal insufficiency. A randomized trial has demonstrated that the addition of ketorolac to morphine PCA can reduce the prevalence of myocardial ischemia following total joint arthroplasty. Whether this is due to improved analgesia or anti-platelet effects is not clear at this time. However, concerns about increased postoperative hemorrhage make the use of these therapies in surgical patients controversial. A decision analysis has suggested that the benefits of aspirin in vascular surgery patients exceed the risks. COX-2 inhibitors are effective analgesics in the perioperative period. However, their chronic use does not protect the heart as much as do NSAIDs with direct platelet actions, and they may impair preconditioning. COX2 drugs use appears contraindicated in cardiac surgery, and possibly in vascular surgery, due their prothrombotic and vasoconstrictor effects.

Dual antiplatelet therapy (DAT). Patients who have drug-eluting coronary stents are at increased risk of acute stent thrombosis in the setting of surgery. This may occur because surgery produces a hypercoagulable state, and because surgeons may wish to stop DAT (aspirin and clopidogrel) before surgery to reduce blood loss. However, stent thrombosis has a high associated mortality. Elective surgery should probably be postponed until a year of DAT follow DES placement. When possible, consideration should be given to continuing DAT through the time of surgery. Some work suggests that such patients should have surgery in locations with the availability of invasive cardiologists and a cardiac catheterization lab should stent thrombosis occur.

Alpha2 Agonists. Alpha2 adrenergic receptors at presynaptic sites mediate a reduction in norepinephrine release from presynaptic terminals, thereby decreasing noradrenergic central nervous system transmission and producing sedation, anxiolysis, and analgesia. Clonidine premedication reduces hypertension, tachycardia, and norepinephrine levels in patients undergoing aortic reconstruction. Clonidine also suppresses the normal postoperative increase in fibrinogen levels and antagonizes epinephrine-induced platelet aggregation. Our work has shown that clonidine can reduce intraoperative myocardial ischemia. The more specific alpha2 agonists dexmedetomidine and mivazerol may also reduce postoperative myocardial ischemia.

Statins. These drugs reduce cholesterol and reduce reinfarction in patients with coronary disease. They can reduce coronary calcium, which may be a predictor of perioperative cardiac events in vascular surgery patients. Several large observation studies, meta-analyses, and randomized trials have correlated statin use with reduced rates of

perioperative death and postoperative cardiac events. Recent work from the group in Rotterdam has substantiated their ability to reduce ECG ischemia and troponin release, and work from Paris has shown that stopping chronic statin therapy after surgery is associated with increased cardiovascular complications. Their anti-inflammatory effects may have beneficial effects on numerous other organ systems. As perioperative beta blockade becomes more controversial, statins are becoming that much more popular to prevent cardiovascular complications.

Hyperglycemia. Hyperglycemia appears to impair preconditioning mechanisms. It has been shown to be associated with worse outcomes in surgical ICU patients, CABG patients, and after acute myocardial infarction in nonsurgical patients. Impaired glucose tolerance and insulin sensitivity is common in patients with known or suspected coronary disease and is associated with endothelial dysfunction. Many such patients have not been classified as diabetic before surgery, yet manifest perioperative hyperglycemia. Recent perioperative studies have differed on whether “tight control” improves coronary and other outcomes. However, some payers have begun to target tight control of perioperative glucose levels in CQI and P4P initiatives.

Anemia / Hypothermia. Anemia is associated with an increased prevalence of postoperative myocardial ischemia. Whether more aggressive transfusion lowers this risk is unclear. In high-risk patients and in those who demonstrate myocardial ischemia, we used to routinely transfuse PRBCs to augment hematocrit to 30%. This simple strategy is complicated by studies showing that transfusion (especially of old blood) also increases cardiac risks. The combination of anemia and beta blockade may be particularly problematic. The elusive goal of a blood substitute might allow safer augmentation of oxygen carrying capacity, but to date, the NO scavenging properties of hemoglobin-based preparations may actually be associated with higher rates of perioperative MI than autologous blood. Hypothermia is also associated with postoperative myocardial ischemia; aggressive warming and heat conservation are warranted during and after surgery in high-risk patients.

Managing Acute MI. A cardiologist should see patients with suspected MI as soon as possible. Acute care for myocardial infarction may include prompt reperfusion (thrombolysis and DES placement requiring DAT are generally contraindicated after surgery), therapy with statins, aspirin and beta blockers in those who can tolerate them, the avoidance of calcium entry blockers, and the use of ACE inhibitors or ARBs in those with poor LV function. It is not known if these recommendations are necessarily transferable to the perioperative setting. In patients with evolving myocardial infarction, intraaortic balloon pumping (IABP) can improve coronary blood flow while decreasing workload. Anecdotal reports exist of IABP placement as prophylaxis against postoperative coronary events for NCS, but definitive studies are lacking. IABP use may be particularly risky in patients with peripheral vascular disease.

The Future:

Improvements in our management of these patients appear to be reducing perioperative cardiac morbidity to the point where other organ system dysfunction may be responsible for the majority of in-hospital deaths. If this is true, then we are truly making remarkable strides. At present, there are rapid changes in the understanding of the pathogenesis of coronary artery disease. This may lead to more widespread primary and secondary prevention (cholesterol reduction, reduction of inflammation) and more aggressive and better revascularization (PTCA/stents). These factors might reduce perioperative cardiac complications. Indeed, in the CARP trial, there were no differences in survival of vascular surgery patients with CAD, whether they were randomized to receive coronary revascularization or not before vascular surgery. In both groups, the majority of patients received beta blockers, aspirin, and statins before surgery. Additionally, given improved medical and revascularization therapy, patients previously considered “too sick” for surgery will present to our ORs (for outpatient procedures, no less!) Future improvements in preventing cardiac deterioration after noncardiac surgery may also involve modulation of the adrenergic response (targeted beta blockade, alpha2 agonists, intensive analgesia), inflammation (statins) and the coagulation system. The key will be to identify cost-effective strategies that improve outcome and to identify patients most likely to benefit.

References (with mini-abstracts):

ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). *Anesth Analg.* 106:685-712. 2008

XX

Page 5

Augoustides JG, Patel P. Recent advances in perioperative medicine: highlights from the literature for the cardiothoracic and vascular anesthesiologist. *J Cardiothorac Vasc Anesth.* 2009 Jun;23(3):430-6. (Highlights recent pharmacologic advances, with emphasis on statins and corticosteroids)

Bennett-Guerrero E, Veldman TH, Doctor A, et al. Evolution of adverse changes in stored RBCs. *Proc Natl Acad Sci U S A.* Oct 23;104(43):17063-8. 2007

Boersma E, Poldermans D, Bax JJ, et al. Predictors of cardiac events after major vascular surgery: Role of clinical characteristics, dobutamine echocardiography, and beta-blocker therapy. *JAMA* 285:1865-73, 2001 (defines which patients most likely to benefit from beta blockade)

Brady AR, Gibbs JS, Greenhalgh RM, et al. (POBBLE trial investigators). Perioperative beta-blockade (POBBLE) for patients undergoing infrarenal vascular surgery: results of a randomized double-blind controlled trial. *J Vasc Surg.* 41:602-9. 2005 (Beta blockers do not reduce cardiac risk, but do shorten hospital stay)

de Souza DG, Baum VC, Ballert NM. Late thrombosis of a drug-eluting stent presenting in the perioperative period. *Anesthesiology* 106:1057-9. 2007 (illustrative case report and discussion of dangers of stopping antiplatelet therapy)

Dunkelgrun M, Boersma E, Schouten O, Koopman-van Gemert AW, van Poorten F, Bax JJ, Thomson IR, Poldermans D; Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. Bisoprolol and fluvastatin for the reduction of perioperative cardiac mortality and myocardial infarction in intermediate-risk patients undergoing noncardiovascular surgery: a randomized controlled trial (DECREASE-IV). *Ann Surg.* 2009 Jun;249(6):921-6. (Bisoprolol was associated with a significant reduction of 30-day cardiac death and nonfatal MI, while fluvastatin showed a trend for improved outcome.)

Dunkelgrun M, Schreiner F, Schockman DB, Hoeks SE, Feringa HH, Goei D, Schouten O, Welten GM, Vidakovic R, Noordzij PG, Boersma E, Poldermans D. Usefulness of preoperative oral glucose tolerance testing for perioperative risk stratification in patients scheduled for elective vascular surgery. *Am J Cardiol.* 2008 Feb 15;101(4):526-9. (the prevalence of undiagnosed impaired glucose tolerance and DM is high in vascular patients and is associated with perioperative myocardial ischemia.)

Durazzo AE, Machado FS, Ikeoka DT, et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. *J Vasc Surg* 39:967-75, 2004 (statins started roughly a month before vascular surgery and continued until 2 weeks after surgery reduced cardiac events)

Ellis JE, Drijvers G, Pedlow S, et al. Premedication with oral and transdermal clonidine provides safe and efficacious postoperative sympathectomy. *Anesth Analg* 79:1133-40, 1994 (clonidine premedication reduces heart rate and intraoperative myocardial ischemia)

Feringa HH, Schouten O, Karagiannis SE, et al. Intensity of statin therapy in relation to myocardial ischemia, troponin T release, and clinical cardiac outcome in patients undergoing major vascular surgery. *J Am Coll Cardiol.* 50:1649-56, 2007 (the lower the LDL, the less likely periop CV complications)

Fleisher LA, Poldermans D. Perioperative beta blockade: where do we go from here? *Lancet.* 371(9627):1813-4. 2008 (letter to the editor discussing POISE trial).

Frank SM, Fleisher LA, Breslow MJ, et al. Perioperative maintenance of normothermia reduces the incidence of morbid cardiac events. *JAMA.* 277:1127-34,1997 (warming reduces cardiac complications)

Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. *Circulation.* 115:813-8. 2007

XX

Page 6

Juul AB, Wetterslev J, Gluud C, et al. (DIPOM Trial Group) Effect of perioperative beta blockade in patients with diabetes undergoing major non-cardiac surgery: randomised placebo controlled, blinded multicentre trial. *BMJ*. 2006 Jun 24;332(7556):1482. (Beta blockers not protective)

Kheterpal S, O'Reilly M, Englesbe MJ, Rosenberg AL, Shanks AM, Zhang L, Rothman ED, Campbell DA, Tremper KK. Preoperative and intraoperative predictors of cardiac adverse events after general, vascular, and urological surgery. *Anesthesiology*. 2009 Jan;110(1):58-66. (The inclusion of intraoperative elements improves the ability to predict adverse cardiac events after noncardiac surgery.)

Kim LJ, Martinez EA, Faraday N, et al. Cardiac troponin I predicts short-term mortality in vascular surgery patients. *Circulation* 106:2366-71, 2002 (troponin leak dramatically increases perioperative and 6 month MI risk, with a dose-response relationship)

Koch CG, Li L, Sessler DI, et al. Duration of red-cell storage and complications after cardiac surgery. *N Engl J Med*. 358:1229-39, 2008 (blood > 2 weeks old associated with more death, sepsis, and renal and respiratory failure)

Landesberg G, Beattie WS, Mosseri M, Jaffe AS, Alpert JS. Perioperative myocardial infarction. *Circulation*. 2009 Jun 9;119(22):2936-44. (Multispeciality view of the problem)

Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. *Circulation* 100:1043-9, 1999 (Six independent predictors of complications were identified: high-risk type of surgery, history of ischemic heart disease, history of CHF, history of cerebrovascular disease, preoperative treatment with insulin, and preoperative serum creatinine >2.0 mg/dL.)

Le Manach Y, Perel A, Coriat P, et al. Early and delayed myocardial infarction after abdominal aortic surgery. *Anesthesiology*.102:885-91. 2005 (Intense postoperative cTnI surveillance revealed two types of PMI according to time of appearance and rate of increase in cTnI. The identification of early and delayed PMI may be suggestive of different pathophysiologic mechanisms)

Lindenauer PK, Pekow P, Wang K, Gutierrez B, Benjamin EM. Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery. *JAMA*. 291:2092-9, 2004 (Large retrospective study suggesting that statins are associated with an odds ratio for death of 0.62 in elderly patients undergoing major noncardiac surgery, and that the number needed to treat to prevent one death was 30 among those with a revised cardiac risk index score ≥ 4)

Mangano DT, Layug EL, Wallace A, Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. *N Engl J Med*.335:1713-20, 1996 (perioperative beta blockade with atenolol has survival benefits that last for 2 years)

Mantha S, Foss J, Ellis JE, Roizen MF. Intense cardiac troponin surveillance for long-term benefits is cost-effective in patients undergoing open abdominal aortic surgery: a decision analysis model. *Anesth Analg*. 105:1346-56, 2007 (cost-effectiveness analysis suggesting routine troponin surveillance after open AAA surgery)

McCrath DJ, Cerboni E, Frumento RJ, et al. Thromboelastography maximum amplitude predicts postoperative thrombotic complications including myocardial infarction. *Anesth Analg*. 100:1576-83, 2005 (hypercoagulable states may contribute to periop MI).

McFalls EO, Ward HB, Moritz TE, Goldman S, Krupski WC, et al. Coronary-artery revascularization before elective major vascular surgery. *N Engl J Med*. 351:2795-804, 2004. (Aggressive medical therapy appears as efficacious as coronary revascularization)

NICE-SUGAR Study Investigators, Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, Hébert PC, Heritier S, Heyland DK, McArthur C, McDonald E, Mitchell I, Myburgh JA, Norton R, Potter J, Robinson BG, Ronco JJ. Intensive versus conventional glucose control in critically ill patients. *N Engl J Med*. 2009 Mar 26;360(13):1283-97. (In this large, international, randomized trial, intensive glucose control increased mortality among adults in the ICU: a blood glucose target of 180 mg or less per deciliter resulted in lower mortality than did a target of 81 to 108 mg per deciliter.)

Norris EJ, Beattie C, Perler BA, et al. Double-masked randomized trial comparing alternate combinations of intraoperative anesthesia and postoperative analgesia in abdominal aortic surgery. *Anesthesiology* 95:1054-67, 2001 (well-designed trial suggesting that anesthetic technique does not affect cardiac outcome after abdominal aortic surgery if heart rate is well controlled in the ICU)

Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. *N Engl J Med.* 352:1081-91. 2005 (myocardial infarction, cardiac arrest, stroke, and pulmonary embolism were more frequent among the patients given COX-2s than among those given placebo)

POISE Study Group, Devereaux PJ, Yang H, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. *Lancet* 371(9627):1839-47. 2008 (fixed-dose long-acting metoprolol reduces myocardial ischemia, but increases stroke)

Poldermans D, Boersma E, Bax JJ, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. *N Engl J Med.* 341:1789-94, 1999 (perioperative beta blockade reduces perioperative mortality and infarction in high risk vascular surgery)

Poldermans D, Schouten O, Vidakovic R, et al (DECREASE Study Group). A clinical randomized trial to evaluate the safety of a noninvasive approach in high-risk patients undergoing major vascular surgery: the DECREASE-V Pilot Study. *J Am Coll Cardiol.* 49:1763-9, 2007 (aggressive beta-blockade superior to stress testing approach)

Rodgers A, Walker N, Schug S, McKee A, Kehlet H, van Zundert A, Sage D, Futter M, Saville G, Clark T, MacMahon S. Reduction of postoperative mortality and morbidity with epidural or spinal anaesthesia: results from overview of randomised trials. *BMJ.* 321:1493-7, 2000. (regional anesthesia, especially spinals and thoracic epidurals, may be associated with reduced perioperative death and myocardial infarction)

Tanaka K, Ludwig LM, Kersten JR, Pagel PS, Warltier DC. Mechanisms of cardioprotection by volatile anesthetics. *Anesthesiology* 100:707-21. 2004 (Excellent review)

van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in the critically ill patients. *N Engl J Med.* 345:1359-67, 2001. (Tight glucose control between 80 and 110 mg/dL reduces mortality in surgical ICU patients)

Zaugg M, Tagliente T, Lucchinetti E, Jacobs E, Krol M, Bodian C, Reich DL, Silverstein JH. Beneficial effects from beta-adrenergic blockade in elderly patients undergoing noncardiac surgery. *Anesthesiology* 91:1674-86, 1999 (beta blockade not only reduces troponin release, but hastens emergence and improves analgesia after general anesthesia)

Zaugg M, Bestmann L, Wacker J, et al. Adrenergic receptor genotype but not perioperative bisoprolol therapy may determine cardiovascular outcome in at-risk patients undergoing surgery with spinal block. *Anesthesiology.* 107:33-44, 2007 (adding beta blockade to SAB might not be beneficial; genomics of beta receptors influence outcome).

